|
End-of-day quote
NSE India S.E.
28/09/2026
|
5-day change | 1st Jan Change | ||
| 1,927.80 INR | -1.17% |
|
-4.06% | +41.28% |
| 09-23 | Emcure Pharmaceuticals Limited Approves Final Dividend for the Financial Year Ended March 31, 2026 | CI |
| 09-16 | Gilead Sciences Expands Licensing Agreements for HIV Treatment | MT |
| Market Cap | 366B 3.81B 3.35B 3.17B 2.87B 5.4B 5.43B 37.93B 14.65B 187B 14.3B 13.99B 600B | P/E 2027 * |
30.7x | P/E 2028 * | 24.9x |
|---|---|---|---|---|---|
| Enterprise Value | 372B 3.88B 3.41B 3.22B 2.92B 5.49B 5.52B 38.6B 14.91B 190B 14.55B 14.24B 610B | EV / Sales 2027 * |
3.51x | EV / Sales 2028 * | 3.03x |
| Free-Float |
18.25% | Yield 2027 * |
0.21% | Yield 2028 * | 0.25% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| EMCURE | End-of-day quote | |
Bombay S.E.
| EMCURE | Delayed |
Last Transcript: Emcure Pharmaceuticals Limited
| 1 day | -1.17% | ||
| 1 week | -4.06% | ||
| Current month | +3.91% | ||
| 1 month | +3.12% | ||
| 3 months | +2.53% | ||
| 6 months | +16.65% | ||
| Current year | +41.28% |
| 1 week | 1,918.1 |  | 1,992.3 |
| 1 month | 1,835 | | 2,100.7 |
| Current year | 1,381 | | 2,100.7 |
| 1 year | 1,260 | | 2,100.7 |
| 3 years | 889 | | 2,100.7 |
| 5 years | 889 | | 2,100.7 |
| 10 years | 889 | | 2,100.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 75 | 16/04/1981 | |
| Director of Finance/CFO | - | 01/10/2003 | |
| Compliance Officer | - | 04/02/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 73 | 23/07/2001 | |
| Chairman | 75 | 21/09/2026 | |
| Director/Board Member | 49 | 28/07/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.17% | -4.06% | +50.12% | - | 3.86B | |
| +0.11% | +1.71% | +63.52% | +117.61% | 1,055B | |
| +0.27% | +0.92% | +51.33% | +73.35% | 654B | |
| +0.73% | +0.68% | +20.70% | +74.90% | 467B | |
| -1.36% | -2.58% | +40.20% | +42.33% | 348B | |
| +1.34% | +4.53% | +23.37% | +29.55% | 275B | |
| -0.48% | -0.54% | +13.56% | +13.50% | 258B | |
| +0.85% | +6.35% | +53.17% | +54.39% | 224B | |
| +0.85% | +1.10% | +35.78% | +101.82% | 187B | |
| -0.30% | -2.98% | -27.62% | -61.28% | 171B | |
| Average | -0.00% | +0.23% | +32.41% | +49.57% | 364.22B | |
| Weighted average by Cap. | -0.05% | +1.00% | +40.70% | +69.85% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 106B 1.1B 971M 918M 832M 1.56B 1.57B 10.99B 4.24B 54.05B 4.14B 4.05B 174B | 120B 1.25B 1.1B 1.04B 941M 1.77B 1.78B 12.42B 4.8B 61.07B 4.68B 4.58B 196B |
| Net income | 11.87B 124M 109M 103M 93.28M 175M 176M 1.23B 476M 6.06B 464M 454M 19.46B | 14.59B 152M 134M 126M 115M 215M 217M 1.51B 584M 7.44B 570M 558M 23.92B |
| Net Debt | 6.38B 66.51M 58.49M 55.31M 50.17M 94.22M 94.77M 662M 256M 3.26B 250M 244M 10.47B | -3.28B -34.15M -30.04M -28.4M -25.76M -48.38M -48.66M -340M -131M -1.67B -128M -125M -5.38B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/09/26 | ₹1,927.80 | -1.17% | 39,044 |
| 25/09/26 | ₹1,950.60 | -0.08% | 32,384 |
| 24/09/26 | ₹1,952.10 | -1.49% | 47,459 |
| 23/09/26 | ₹1,981.70 | +0.34% | 37,562 |
| 22/09/26 | ₹1,975.00 | -1.71% | 41,985 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EMCURE Stock
Select your edition
All financial news and data tailored to specific country editions
